CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of
investigational RNA interference (RNAi) therapeutics, today announced
that the Company will release its third quarter 2016 financial results
after market close on Monday, November 7, 2016.
Management will conduct a conference call at 4:30 p.m. ET that day to
discuss the Company's financial results and provide a general business
update. The conference call will be webcast live via the internet and
will be available on the "Investors & Media" section of the Dicerna
The webcast will also be archived on the Company's website.
The call can also be accessed by dialing (855) 453-3834 or (484)
756-4306 (international), and referencing conference ID 10030267 prior
to the start of the call. After the conference call, a replay will be
available until November 14, 2016. To access the replay, please dial
(855) 859-2056 or (404) 537-3406, and refer to conference ID 10030267.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on
the discovery and development of innovative RNA interference
(RNAi)-based therapeutics for rare diseases involving the liver and for
other diseases involving the liver such as chronic liver diseases,
cardiovascular diseases, and viral infectious diseases. The Company is
using its proprietary GalXC™ RNAi technology platform to build a broad
pipeline in these core therapeutic areas. Dicerna is pursuing target
genes where connections between target gene and diseases are well
understood and documented. The Company intends to discover, develop and
commercialize these novel therapeutics either on its own or in
collaboration with pharmaceutical partners. For more information, please
View source version on businesswire.com: http://www.businesswire.com/news/home/20161031005935/en/
Rx Communications Group
Van Rees, 973-442-1555 ext. 111
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media